samedan logo

 
 
spacer
home > ebr > spring 2003 > spr analysis of rationally designed anti-her2 exocyclic mimetics of antibodies
PUBLICATIONS
European Biopharmaceutical Review

SPR Analysis of Rationally Designed Anti-HER2 Exocyclic Mimetics of Antibodies

A series of peptide mimetics, based on the structure of the CDR3 loop of the anti-HER2 mAb 4D5, an anti-oncoprotein therapeutic monoclonal antibody, have been designed. The peptides can disable the tyrosine kinase, p185HER2/neu (HER2), an oncoprotein commonly expressed in human breast, ovarian and colon cancers. In SPR studies, the peptides have been shown to directly bind to HER2 and to compete with mAb 4D5 for receptor binding. Dissociation rate constants were shown to be important determinants of anti-tumorigenic activity of the peptides.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ramachandran Murali, Assistant Professor in the Department of Pathology and Laboratory of Medicine at the University of Pennsylvania, USA

Dr Ramachandran Murali

Dr Ramachandran Murali is Assistant Professor in the Department of Pathology and Laboratory of Medicine, University of Pennsylvania School of Medicine. He is also a visiting academic at the Sir William Dunn School of Pathology, Oxford University, UK and a well trained and established structural biologist. He obtained his doctoral degree in Biophysics from the University of Madras, India, one of the pioneering institutes for structural biology in India.

Since then Dr Murali has expanded his expertise in macromolecular crystallography, immunology and cancer biology. His laboratory is mainly interested in the structure and function aspects of cell surface receptors relevant for cancer biology and immunology. His contributions include antibody structures, small molecule modifiers of receptors which have therapeutic applications in cancer biology, and autoimmune pathologies. He has developed several therapeutically relevant small molecules in the Department of Pathology and Laboratory Medicine, Center for Receptor Biology and Cell Growth at the University of Pennsylvania School of Medicine.


spacer
Dr Ramachandran Murali
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration

Philadelphia, PA – November 14, 2019: Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
More info >>

White Papers
 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement